Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

strating a clinical benefit, such as improvement in disease-related symptoms or increased survival

Important Safety Information(1)

Severe (NCI Grades 3/4) lab abnormalities (400 mg/day; 600 mg/day)- including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia (0%; 1%), and hepatotoxicity (6%; 8%)-and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (eg, pleural effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain (11%; 4%), nausea (6%; 4%), diarrhea (3%; 7%), and musculoskeletal pain (6%; 1%) were reported among patients receiving Gleevec

Some patients (5%) were reported to have severe GI bleeds and/or intratumoral bleeds. GI tumor sites may have been the source of GI bleeds

Patients should be weighed and monitored regularly for signs and symptoms of edema, which can be serious or life-threatening. There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, increased intracranial pressure, papilledema, and gastrointestinal (GI) perforation

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated

Bullous dermatologic reactions (eg, erythema multiforme and Stevens- Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resolution or improvement of the bullous reaction

Dose adjustments ma
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
(Date:11/24/2014)... 2014 Juno Therapeutics today announced that ... the company,s JCAR015 chimeric antigen receptor product candidate. ... or refractory B-cell acute lymphoblastic leukemia and was ... Cancer Center, where Phase 1 clinical trials are ... is important news for patients who may benefit ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... , March 12 Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused ... today reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical ... ... , ...
... PARK, Ill., March 11 The U.S. ... the supplemental new drug application (sNDA) of a new ... Depot (leuprolide acetate for depot suspension) ... cancer.  Palliative treatment helps to relieve symptoms associated with ...
Cached Medicine Technology:Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7
(Date:11/26/2014)... Angeles, California (PRWEB) November 26, 2014 ... score of 3.9 out of 5. This score represents ... over the three years to 2014 as a result ... for medical suction machines, which are largely considered nondiscretionary. ... the purchasing process, buyers have some degree of flexibility, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 News ... showcase expanded capabilities at RSNA 2014 in Chicago. ... manage and share diagnostic images, photos, videos and ... Perceptive’s booth #8107 will learn more about these ... acquired technologies and partner initiatives – that enable ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Vultures have developed highly specialized ... when eating dead animals, researchers report. The new ... the faces and in the guts of 50 turkey ... average, the faces of the vultures had more than ... their guts, the study found. The findings suggest ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 ... Food and Drug Administration will have many restaurant chains posting ... to movie theater popcorn and ice cream parlor fare. ... home, often consuming less nutritious food and underestimating the calories ... Monday afternoon news conference. Although listing calorie counts ...
(Date:11/24/2014)... 2014 From embedded sensors and biometrics to ... technology will take center stage at the FitnessTech Summit ... the 2015 International CES® , January 6, 2015 in ... Bellini 2004). The bond between fitness and technology is stronger ... devices and more about the human body. , “Fitness technology ...
Breaking Medicine News(10 mins):Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
... LONDON, Sept. 8 The 2009 Frost & Sullivan ... Award is presented to Pronova BioPharma ASA. The company,s first ... derived prescription drug. Branded Omacor in Europe and Asia ... adjunct to diet for the treatment of elevated levels of ...
... ... be used learn how African health care providers are collaborating with physicians from Johns ... in Africa. , ... Baltimore, Maryland (PRWEB) September 8, 2009 -- The recent tragic death of Michael Jackson ...
... , , WASHINGTON, Sept. 8 ... the nation on health care reform, a new analysis by ... illegal immigrants could receive benefits under the House health reform ... are not eligible for the new taxpayer-funded affordability credits, there ...
... ... Marriage and Family Therapist and Clinical Hypnotherapist David Swindoll now available to view on YouTube. ... (Vocus) September 7, 2009 ... over thirty years. He has found the use of ColorAlchemy and color therapy ...
... TUCSON, Ariz., Sept. 7 Despite the effects of ... Lewis MDA Telethon over Labor Day nonetheless totaled $60,481,231 million. , ... ) , , MDA National Chairman and Telethon ... support from Telethon viewers even during hard times. , , ...
... Prevention efforts focused on the community pay off, study ... abuse and delinquent behavior among teens was significantly reduced ... new study found. , The Communities That Care prevention ... in seven states, slashed alcohol use by eighth graders ...
Cached Medicine News:Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 2Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 4Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 5Health News:Medical Student Wins Travel Scholarship to Kenya to Study Operative Care in Africa 2Health News:Medical Student Wins Travel Scholarship to Kenya to Study Operative Care in Africa 3Health News:Health Bill Could Benefit 6.6 Million Illegals 2Health News:Health Bill Could Benefit 6.6 Million Illegals 3Health News:Licensed Marriage and Family Therapist and Clinical Hypnotherapist Provides Powerful Video Testimony for ColorAlchemy and Color Therapy 2Health News:Licensed Marriage and Family Therapist and Clinical Hypnotherapist Provides Powerful Video Testimony for ColorAlchemy and Color Therapy 3Health News:Jerry Lewis MDA Telethon Achieves $60.5 Million 2Health News:Program Curbs Teen Substance Abuse, Delinquency 2
... Surgical Thoracic Trocar consists of ... and a flexible sleeve which ... or laceration to internal structures. ... holes to secure it to ...
... believe that the trocar should be a ... precision and speeding the process. So we ... that meets the needs of the most ... - The only trocar that affords the ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: